Federal Register / Vol. 71, No.
117 / Monday, June 19, 2006 / Notices
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than August 18, 2006.
Dated: June 9, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–9508 Filed 6–16–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated January 11, 2006, and
published in the Federal Register on
January 23, 2006 (71 FR 3543), Cerilliant
Corporation, 811 Paloma Drive, Suite A,
Round Rock, Texas 78664, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in Schedules I and II:
Drug
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
N,N-Dimethylamphetamine (1480)
Aminorex (1585) ...........................
4-Methylaminorex (cis isomer)
(1590).
Gamma Hydroxybutyric acid
(2010).
Methaqualone (2565) ...................
Alpha-Ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
jlentini on PROD1PC65 with NOTICES
Mescaline (7381) ..........................
3,4,5-Trimethoxyamphetamine
(7390).
4-Bromo-2,5-
dimethoxyamphetamine (7391).
VerDate Aug<31>2005 16:46 Jun 16, 2006 Jkt 208001
35311
Drug Schedule Drug Schedule
4-Bromo-2,5- I 1-Phenylcyclohexylamine (7460) II
dimethoxyphenethylamine Phencyclidine (7471) .................... II
(7392). 1- II
4-Methyl-2,5- I Piperidinocyclohexanecarbonitr-
dimethoxyamphetamine (7395). ile (8603).
2,5-Dimethoxyamphetamine I Alphaprodine (9010) ..................... II
(7396). Cocaine (9041) ............................. II
2,5-Dimethoxy-4- I Codeine (9050) ............................. II
ethylamphetamine (7399). Dihydrocodeine (9120) ................. II
3,4-Methylenedioxyamphetamine I Oxycodone (9143) ........................ II
(7400). Hydromorphone (9150) ................ II
5-Methoxy-3,4- I Diphenoxylate (9170) ................... II
methylenedioxyamphetamine Benzoylecgonine (9180) ............... II
(7401). Ethylmorphine (9190) ................... II
N-Hydroxy-3,4- I Hydrocodone (9193) ..................... II
methylendioxyamphetamine Levomethorphan (9210) ............... II
(7402). Levorphanol (9220) ...................... II
3,4-Methylendioxy-N- I Isomethadone (9226) ................... II
ethylamphetamine (7404). Meperidine (9230) ........................ II
3,4- I Methadone (9250) ........................ II
Methylenedioxymethamphetam- Methadone intermediate (9254) ... II
ine (7405). Dextropropoxyphene, bulk (non- II
4-Methoxyamphetamine (7411) ... I dosage forms) (9273).
Bufotenine (7433) ......................... I Morphine (9300) ........................... II
Diethyltryptamine (7434) .............. I Thebaine (9333) ........................... II
Dimethyltryptamine (7435) ........... I
Levo-alphacetylmethadol (9648) .. II
Psilocybin (7437) .......................... I Oxymorphone (9652) ................... II
Psilocyn (7438) ............................. I
Noroxymorphone (9668) .............. II
Acetyldihydrocodeine (9051) ........ I Racemethorphan (9732) .............. II
Benzylmorphine (9052) ................ I Alfentanil (9737) ........................... II
Codeine-N-oxide (9053) ............... I
Sufentanil (9740) .......................... II
Dihydromorphine (9145) ............... I
Fentanyl (9801) ............................ II
Heroin (9200) ............................... I
Hydromorphinol (9301) ................. I
Methyldihydromorphine (9304) ..... I The company plans to manufacture
Morphine-N-oxide (9307) ............. I small quantities of the listed controlled
Normorphine (9313) ..................... I substances to make reference standards
Pholcodine (9314) ........................ I which will be distributed to their
Acetylmethadol (9601) ................. I
Allylprodine (9602) ....................... I
customers.
Alphacetylmethadol except levo- I No comments or objections have been
alphacetylmethadol (9603). received. DEA has considered the
Alphameprodine (9604) ................ I factors in 21 U.S.C. 823(a) and
Alphamethadol (9605) .................. I determined that the registration of
Betacetylmethadol (9607) ............ I
Cerilliant Corporation to manufacture
Betameprodine (9608) .................. I
Betamethadol (9609) .................... I the listed basic classes of controlled
Betaprodine (9611) ....................... I substances is consistent with the public
Hydroxypethidine (9627) .............. I interest at this time. DEA has
Noracymethadol (9633) ................ I investigated Cerilliant Corporation to
Norlevorphanol (9634) .................. I ensure that the company’s registration is
Normethadone (9635) .................. I consistent with the public interest. The
Trimeperidine (9646) .................... I investigation has included inspection
Schedule
Phenomorphan (9647) ................. I
and testing of the company’s physical
Para-Fluorofentanyl (9812) .......... I
I security systems, verification of the
3-Methylfentanyl (9813) ................ I
I company’s compliance with state and
Alpha-Methylfentanyl (9814) ........ I
I Acetyl-alpha-methylfentanyl I local laws, and a review of the
I (9815). company’s background and history.
I Beta-hydroxyfentanyl (9830) ........ I Therefore, pursuant to 21 U.S.C. 823,
I Beta-hydroxy-3-methylfentanyl I
and in accordance with 21 CFR 1301.33,
(9831). the above named company is granted
I Alpha-Methylthiofentanyl (9832) ... I
registration as a bulk manufacturer of
3-Methylthiofentanyl (9833) .......... I
I Thiofentanyl (9835) ...................... I
the basic classes of controlled
I Amphetamine (1100) .................... II substances listed.
I Methamphetamine (1105) ............ II Dated: June 12, 2006.
I Phenmetrazine (1631) .................. II Joseph T. Rannazzisi,
I
Methylphenidate (1724) ................ II
I Amobarbital (2125) ....................... II Deputy Assistant Administrator, Office of
I Pentobarbital (2270) ..................... II Diversion Control, Drug Enforcement
Secobarbital (2315) ...................... II Administration.
I Glutethimide (2550) ...................... II [FR Doc. E6–9504 Filed 6–16–06; 8:45 am]
Nabilone (7379) ............................ II BILLING CODE 4410–09–P
PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 E:\FR\FM\19JNN1.SGM 19JNN1